Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

The research and investment firm believes Nvidia ( NASDAQ: NVDA) will slice into AMD's market share in these two areas.

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook.

Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD). Price Action ...